JP2013522320A - 安定なボルテゾミブ製剤 - Google Patents
安定なボルテゾミブ製剤 Download PDFInfo
- Publication number
- JP2013522320A JP2013522320A JP2013500229A JP2013500229A JP2013522320A JP 2013522320 A JP2013522320 A JP 2013522320A JP 2013500229 A JP2013500229 A JP 2013500229A JP 2013500229 A JP2013500229 A JP 2013500229A JP 2013522320 A JP2013522320 A JP 2013522320A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bortezomib
- composition according
- solvent system
- heterobifunctional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (21)
- ボルテゾミブを含む液状製剤を含む薬学組成物であって、
前記液状製剤は注射に適していて水の総含有量が15体積%以下である実質的に非水性の溶媒系であり、
前記溶媒系は主成分としてプロピレングリコールを含み、
前記ボルテゾミブは少なくとも1 mg/mlの濃度で存在し、
前記溶媒系は、前記液状製剤を環境条件において少なくとも3ヶ月以上貯蔵した場合にボルテゾミブの減成を10重量%未満のレベルに維持するように調製される、
薬学組成物。 - 前記実質的に非水性の溶媒系が少なくとも50体積%のプロピレングリコールを含む、請求項1に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が少なくとも75体積%のプロピレングリコールを含む、請求項2に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が100体積%のプロピレングリコールを含む、請求項2に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が25体積%以下の量の極性溶媒をさらに含む、請求項1に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が20体積%以下の量の極性溶媒を含む、請求項5に記載の薬学組成物。
- 前記極性溶媒がエタノールである、請求項5又は6に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が50体積%以下の量の極性溶媒をさらに含む、請求項1に記載の薬学組成物。
- 前記実質的に非水性の溶媒系が10体積%以下の量の極性溶媒をさらに含む、請求項1に記載の薬学組成物。
- 前記極性溶媒が水である、請求項8に記載の薬学組成物。
- ボルテゾミブ及びヘテロ二官能性ルイス塩基を含む製剤を含む薬学組成物であって、
前記ボルテゾミブ及びヘテロ二官能性ルイス塩基はルイス供与体‐受容体複合体の形態で前記製剤中に共存し、
前記ヘテロ二官能性ルイス塩基は、第一の供与基及び第二の供与基を有し、前記第一の供与基及び第二の供与基は、-NH2、-SH、COOH、及び-OHからなる群から選択され、かつ、同一のものではなく、
前記製剤は凍結乾燥状態又は溶液状態である、
薬学組成物。 - ボルテゾミブ及びヘテロ二官能性ルイス塩基が1:100〜1:200の比率で存在する、請求項11に記載の薬学組成物。
- ボルテゾミブ及びヘテロ二官能性ルイス塩基が1:10〜1:100の比率で存在する、請求項11に記載の薬学組成物。
- ボルテゾミブ及びヘテロ二官能性ルイス塩基が1:1〜1:10の比率で存在する、請求項11に記載の薬学組成物。
- 前記ヘテロ二官能性ルイス塩基が、アミノ酸、ペプチド、及び置換ポリエチレングリコールからなる群から選択される、請求項11に記載の薬学組成物。
- 前記アミノ酸が天然アミノ酸又はN-アセチル化アミノ酸である、請求項15に記載の薬学組成物。
- 前記ペプチドがジペプチド又はトリペプチドである、請求項15に記載の薬学組成物。
- バッファー剤、凍結乾燥保護剤、凍結保護剤、保存剤、及び抗酸化剤のうちの少なくとも一つをさらに含む、請求項11に記載の薬学組成物。
- 前記製剤が凍結乾燥状態である、請求項11に記載の薬学組成物。
- 請求項1又は11に記載の薬学組成物を含む容器であって、バイアル、アンプル、静注用バッグ、又は注射器であり、任意で複数回使用容器としての構成を有する、容器。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31508010P | 2010-03-18 | 2010-03-18 | |
US61/315,080 | 2010-03-18 | ||
PCT/US2011/029003 WO2011116286A2 (en) | 2010-03-18 | 2011-03-18 | Stable bortezomib formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013522320A true JP2013522320A (ja) | 2013-06-13 |
JP5661912B2 JP5661912B2 (ja) | 2015-01-28 |
Family
ID=44647709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013500229A Expired - Fee Related JP5661912B2 (ja) | 2010-03-18 | 2011-03-18 | 安定なボルテゾミブ製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9061037B2 (ja) |
EP (1) | EP2547333B1 (ja) |
JP (1) | JP5661912B2 (ja) |
KR (1) | KR101530942B1 (ja) |
AU (1) | AU2011227083B2 (ja) |
NZ (1) | NZ602392A (ja) |
RU (1) | RU2529800C2 (ja) |
WO (1) | WO2011116286A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016534111A (ja) * | 2013-08-23 | 2016-11-04 | シントン・ビー.ブイ.Synthon B.V. | ボルテゾミブを含む医薬組成物 |
JP2018012660A (ja) * | 2016-07-20 | 2018-01-25 | 日本化薬株式会社 | ボルテゾミブを含有する医薬組成物 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
NZ602392A (en) | 2010-03-18 | 2014-03-28 | Innopharma Inc | Stable bortezomib formulations |
US8962572B2 (en) | 2010-10-05 | 2015-02-24 | Fresenius Kabi Usa, Llc | Bortezomib formulations |
WO2013128419A2 (en) * | 2012-03-02 | 2013-09-06 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
CA2784240C (en) * | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
EP3102585B1 (en) | 2014-02-03 | 2021-05-19 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
WO2016059592A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of peptide drugs and process for its preparation |
US20170239335A1 (en) * | 2014-10-16 | 2017-08-24 | Piramal Enterprises Limited | Stable injectable composition of pharmaceutically active agents and process for its preparation |
WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
WO2016110870A1 (en) * | 2015-01-07 | 2016-07-14 | Emcure Pharmaceuticals Limited | Pharmaceutical composition of bortezomid |
EP3288955B1 (en) * | 2015-04-29 | 2019-09-18 | Nanosilical Devices Srl | Bortezomib-based delivery system |
EP3120836A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Gebrauchsfertige bortezomib-lösung |
EP3120837A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Verfahren zur herstellung einer bortezomibester-lösung |
CN107224569A (zh) * | 2016-03-26 | 2017-10-03 | 复旦大学 | 一种硼替佐米水溶性药用组合物及其制备方法和用途 |
KR101807462B1 (ko) * | 2017-03-09 | 2017-12-08 | 씨제이헬스케어 주식회사 | 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법 |
WO2019097413A1 (en) * | 2017-11-15 | 2019-05-23 | Intas Pharmaceuticals Ltd. | Stable non-aqueous pharmaceutical compositions |
US10988489B2 (en) * | 2018-11-27 | 2021-04-27 | Clark Atlanta University | Organoboranes useful as electrolytes for lithium batteries |
WO2022094396A1 (en) * | 2020-11-02 | 2022-05-05 | Spes Pharmaceuticals Inc. | Aqueous compositions of bortezomib |
US11805323B2 (en) | 2021-04-01 | 2023-10-31 | Brillnics Singapore Pte. Ltd. | Solid-state imaging device, method for driving solid-state imaging device, and electronic apparatus |
US20230062279A1 (en) | 2021-08-12 | 2023-03-02 | Extrovis Ag | Pharmaceutical compositions of bortezomib |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000336041A (ja) * | 1999-03-19 | 2000-12-05 | Wakamoto Pharmaceut Co Ltd | プロピレングリコールを含有することを特徴とするウリナスタチン含有水性製剤 |
JP2003508436A (ja) * | 1999-08-30 | 2003-03-04 | デビオファーム ソシエテ アノニム | 非経口投与のための医薬として安定なオキザリプラチナム製剤 |
JP2004517932A (ja) * | 2001-01-25 | 2004-06-17 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ボロン酸化合物製剤 |
WO2004096229A1 (ja) * | 2003-04-30 | 2004-11-11 | Dainippon Sumitomo Pharma Co., Ltd. | 溶液医薬組成物 |
WO2006134864A1 (ja) * | 2005-06-13 | 2006-12-21 | Dainippon Sumitomo Pharma Co., Ltd. | 可溶化型製剤 |
JP2007513084A (ja) * | 2003-11-20 | 2007-05-24 | ノボ ノルディスク アクティーゼルスカブ | 注入デバイスにおける生成および使用に最適なプロピレングリコール含有ペプチド処方 |
WO2010089768A2 (en) * | 2009-01-09 | 2010-08-12 | Sun Pharma Advanced Research Company Limited | Pharmaceutical composition |
WO2010114982A2 (en) * | 2009-04-03 | 2010-10-07 | Cephalon, Inc. | Lyophilization cakes of proteasome inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525309A (en) | 1983-03-15 | 1985-06-25 | Washington State University Research Foundation, Inc. | Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5780545A (en) * | 1996-03-08 | 1998-07-14 | Eastman Kodak Company | Stable release agents |
ES2457593T3 (es) | 2004-03-30 | 2014-04-28 | Millennium Pharmaceuticals, Inc. | Síntesis de bortezomib |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US20060084691A1 (en) | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
US20090062222A1 (en) | 2005-09-29 | 2009-03-05 | Trustees Of Boston University | Methods for Sensitizing Cancer Cells to Inhibitors |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びボルテゾミブを用いる方法 |
JP2009514623A (ja) * | 2005-11-08 | 2009-04-09 | ピカルス エンファオ エスアー | 腫瘍壊死因子−アルファ阻害剤を備えた医療用ステント |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
EP2024362A4 (en) | 2006-05-16 | 2012-01-25 | Pharmascience Inc | IAP BIR DOMAIN BINDING COMPOUNDS |
EP2086323A4 (en) | 2006-11-03 | 2010-01-06 | Univ Maryland | METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA |
WO2008075376A1 (en) | 2006-12-18 | 2008-06-26 | Natco Pharma Limited | Polymorphic forms of bortezomib and process for their preparation |
WO2009026427A2 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
JP2010539183A (ja) | 2007-09-12 | 2010-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ボルテゾミブおよびその生成のためのプロセス |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
WO2009102707A2 (en) | 2008-02-11 | 2009-08-20 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
EP2344165A4 (en) | 2008-10-01 | 2012-12-05 | Reddys Lab Ltd Dr | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS |
US20100137246A1 (en) | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
US20100135984A1 (en) | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
NZ602392A (en) | 2010-03-18 | 2014-03-28 | Innopharma Inc | Stable bortezomib formulations |
US8263578B2 (en) * | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
-
2011
- 2011-03-18 NZ NZ602392A patent/NZ602392A/en not_active IP Right Cessation
- 2011-03-18 EP EP11757060.6A patent/EP2547333B1/en not_active Not-in-force
- 2011-03-18 AU AU2011227083A patent/AU2011227083B2/en not_active Ceased
- 2011-03-18 RU RU2012144316/15A patent/RU2529800C2/ru not_active IP Right Cessation
- 2011-03-18 JP JP2013500229A patent/JP5661912B2/ja not_active Expired - Fee Related
- 2011-03-18 KR KR1020127027272A patent/KR101530942B1/ko not_active IP Right Cessation
- 2011-03-18 US US13/051,102 patent/US9061037B2/en not_active Expired - Fee Related
- 2011-03-18 WO PCT/US2011/029003 patent/WO2011116286A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000336041A (ja) * | 1999-03-19 | 2000-12-05 | Wakamoto Pharmaceut Co Ltd | プロピレングリコールを含有することを特徴とするウリナスタチン含有水性製剤 |
JP2003508436A (ja) * | 1999-08-30 | 2003-03-04 | デビオファーム ソシエテ アノニム | 非経口投与のための医薬として安定なオキザリプラチナム製剤 |
JP2004517932A (ja) * | 2001-01-25 | 2004-06-17 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ボロン酸化合物製剤 |
JP2004517931A (ja) * | 2001-01-25 | 2004-06-17 | アメリカ合衆国 | ボロン酸化合物製剤 |
WO2004096229A1 (ja) * | 2003-04-30 | 2004-11-11 | Dainippon Sumitomo Pharma Co., Ltd. | 溶液医薬組成物 |
JP2007513084A (ja) * | 2003-11-20 | 2007-05-24 | ノボ ノルディスク アクティーゼルスカブ | 注入デバイスにおける生成および使用に最適なプロピレングリコール含有ペプチド処方 |
WO2006134864A1 (ja) * | 2005-06-13 | 2006-12-21 | Dainippon Sumitomo Pharma Co., Ltd. | 可溶化型製剤 |
WO2010089768A2 (en) * | 2009-01-09 | 2010-08-12 | Sun Pharma Advanced Research Company Limited | Pharmaceutical composition |
WO2010114982A2 (en) * | 2009-04-03 | 2010-10-07 | Cephalon, Inc. | Lyophilization cakes of proteasome inhibitors |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016534111A (ja) * | 2013-08-23 | 2016-11-04 | シントン・ビー.ブイ.Synthon B.V. | ボルテゾミブを含む医薬組成物 |
JP2018012660A (ja) * | 2016-07-20 | 2018-01-25 | 日本化薬株式会社 | ボルテゾミブを含有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
RU2012144316A (ru) | 2014-04-27 |
EP2547333A4 (en) | 2014-04-30 |
AU2011227083A1 (en) | 2012-10-04 |
US20110230441A1 (en) | 2011-09-22 |
US9061037B2 (en) | 2015-06-23 |
EP2547333B1 (en) | 2017-08-23 |
WO2011116286A4 (en) | 2012-05-10 |
NZ602392A (en) | 2014-03-28 |
JP5661912B2 (ja) | 2015-01-28 |
AU2011227083B2 (en) | 2013-07-18 |
WO2011116286A2 (en) | 2011-09-22 |
KR20130010902A (ko) | 2013-01-29 |
EP2547333A2 (en) | 2013-01-23 |
KR101530942B1 (ko) | 2015-06-23 |
WO2011116286A3 (en) | 2012-03-22 |
RU2529800C2 (ru) | 2014-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5661912B2 (ja) | 安定なボルテゾミブ製剤 | |
US9180093B2 (en) | Stable bortezomib formulations | |
JP5774561B2 (ja) | 安定なボルテゾミブ製剤 | |
JP6133943B2 (ja) | ベンダムスチンの製剤 | |
EP2666463A1 (en) | Stabilized liquid composition comprising pemetrexed | |
US10314880B2 (en) | Composition comprising bortezomib | |
WO2016059592A1 (en) | Stable injectable composition of peptide drugs and process for its preparation | |
US20200188478A1 (en) | Pre-mixed, ready to use vancomycin compositions | |
WO2016001905A2 (en) | Stable liquid ready-to-use injectable formulation of bortezomib | |
US11752164B2 (en) | Bortezomib compositions | |
WO2020089826A1 (en) | Ready to use intravenous infusion of brivaracetam or salt thereof | |
WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
US10682326B1 (en) | Stable melphalan liquid injectable formulations | |
WO2016110870A1 (en) | Pharmaceutical composition of bortezomid | |
EP4134083A1 (en) | Pharmaceutical compositions of bortezomib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20140328 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20140409 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5661912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |